The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
According to reports, Regeneron Pharmaceuticals shares declined in premarket trading following a clinical trial miss for its melanoma treatment. The phase 3 trial of fianlimab failed to reach statistical significance on its primary goal of improving progression-free survival compared to Merck's Keytruda. This failure in the company's most anticipated clinical trial of the year has triggered multiple analyst downgrades.
This setback occurs as the biotech sector faces intense competition, with Merck's Keytruda maintaining its position as the market standard, which continues to pressure competitors' market share per market data. Historically, investors had high expectations for this drug combination to bolster Regeneron's immunotherapy portfolio, but these results may solidify Merck's dominant position in the oncology space.
Sign in to access this content
Sign InREGN shares are being closely monitored at the close of May 18, 2026, as the market reacts to the clinical data and subsequent analyst revisions. Looking ahead, traders are eyeing the upcoming U.S. CPI inflation data on the economic calendar, which could impact broader sector sentiment, while awaiting further guidance from management regarding the future of their clinical pipeline.